Stock·NASDAQ·Healthcare
BioNTech SE (BNTX)
- Market cap
- $22.15B
- Dividend yield
- None
- Street target
- $121.99median of 21 analysts
- 52-week range
- $79.52 $124.00
BNTX stock forecast today
Where BNTX stands today, and what CleaRank Financial AI makes of it.
BNTX at a glance
BioNTech SE (BNTX): Sell, 28/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($97.24 and $97.10).
- Earnings BNTX beat estimates in 2 of the 6 reports in our data, yet fell the next day after every one of them.
- Insiders Insiders sold $74.3M and made no open-market purchases over the last 18 months.
Figures as of October 30, 2026.
CleaRank Financial AI
CleaRank rates BioNTech SE (BNTX) Sell, with a model score of 28/100.
The analysts' outlook lifts the score most: 14 of 21 analysts rate it a buy and the median target is 38.3% above the price. The trend holds it back most: the price is 9.18% below its 200-day average and 9.32% below its 50-day average. The 50-day average stands at $97.24 and the 200-day at $97.10. Over the past year the price fell 15.75%.
Only on CleaRank
Figures we compute ourselves from BNTX's own price, earnings and insider-filing history. Tap one to see it in context.
BNTX stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price below its 50-day average ›
The price of $88.18 is 9.3% below the 50-day simple moving average of $97.24.Price below its 200-day average ›
The price is 9.2% below the 200-day simple moving average of $97.10.50-day average above the 200-day ›
The 50-day average ($97.24) is 0.1% above the 200-day average ($97.10), the arrangement of a rising longer-term trend.In the lower half of its 52-week range ›
The price sits at 19% of its 52-week range, between $79.52 and $124.00.
BNTX share price
Pick a period: each tab shows how far BNTX has moved over it, to the last close.
Today's trading
Where BNTX sits inside today's range and its 52-week range.
BNTX fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
0/3P/S above the sector median ›
The price-to-sales ratio of 7.48 is 120.1% above the sector median of 3.4.Not profitable over the last 12 months ›
Net income over the last 12 months was -$1.9B on revenue of $3.0B, a net margin of -63.6%.Missed estimates in most recent reports ›
BNTX beat the EPS estimate in 2 of the 6 reports in our data.
Key statistics
The headline figures for BNTX.
As of October 30, 2026, BNTX trades at $88.18, with a market value of $22.15B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of BNTX's valuation, growth and risks.
Earnings per share for BNTX over the last 12 months are negative, so its P/E is not meaningful. Market capitalisation is $22.2B, and trailing earnings come to -$7.83 a share.
The company is losing money, with a net margin of -63.64% and an operating margin of -806.63%. Growth trails the sector: revenue fell 59.50% in the most recent available quarter year on year, against a sector median of 8.1%. Shareholders' capital earns -9.30%, below the sector median of 7.3%, measured as return on equity. Rounding out the fundamentals, BNTX reports debt-to-equity of 0.02.
BNTX's most recent available report in our data, dated May 5, 2026, showed EPS of -$1.95 against an estimate of -$1.92, so the result came in weaker than analysts had forecast. The stock dropped 0.25% in the session that followed.
The earnings record shows 2 beats in 6 reports, yet the stock fell in the first session after every one of those 2 beats. The March 10, 2026 report stands out among the few before the latest: a miss of 32.00%, after which the stock rose 8.28%. Analysts' average EPS estimate for this fiscal year is -$4.68, and -$4.81 for next year.
The 30-day standard deviation of BNTX's daily returns is 2.21%; measured against the S&P 500, its beta is 1.25. Until the price regains its moving averages, the trend works against holders. The price is 28.89% below its 52-week high of $124.00. Insiders sold $74.3M over the last 18 months and bought none on the open market, though sales of this kind are often planned in advance and say less than purchases would.
BNTX against the Healthcare sector
How BNTX compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, BNTX trades at 7.48x, +120% versus the sector average of 3.40x.
Return vs XLV: Since May 20, 2025, BNTX has lost 13.3% against a gain of 37.3% for XLV.
Performance against XLV
BNTX and the Healthcare sector fund over the same days.
Revenue and earnings
How much BNTX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 4.3% in FY2025 to €2.9B, from €2.8B a year earlier.
Profit margin: The net margin was -39.6% in FY2025, down from -24.2% the year before.
Loss-making: BNTX lost €1.1B in FY2025.
Earnings reality check
Did BNTX beat what analysts expected, and how did the stock react?
Earnings record: BNTX beat the analyst estimate in 2 of the 6 reports in our data.
Market reaction: The stock fell in the first session after 2 of those 2 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| May 5, 2026after close | -$1.92 | -$1.95 | -1.56% | -0.25% | -1.93% |
| Mar 10, 2026after close | -$0.25 | -$0.33 | -32.00% | +8.28% | +13.08% |
| Nov 3, 2025after close | $0.10 | -$0.12 | -220.00% | +0.84% | +1.07% |
| Aug 4, 2025after close | -$1.41 | -$1.60 | -13.48% | +0.95% | -0.70% |
| May 5, 2025after close | -$2.35 | -$1.73 | +26.38% | -6.29% | -3.79% |
| Mar 10, 2025after close | $0.37 | $1.08 | +191.89% | -6.61% | -4.26% |
Reports after May 5, 2026 are not yet in our data.
As of October 30, 2026, BNTX has beaten the analyst EPS estimate in 2 of the 6 reports in our data and fell in the first trading session after 2 of those beats; its most recent report in our data, on May 5, 2026, came in 1.56% below the estimate and the stock moved -0.25% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
BNTX AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 40.7, in neutral territory.RSI below 50 ›
An RSI of 40.7 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line below zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank Financial AI analysis of BNTX
The score, the reasoning behind it, and what could move the price next.
BNTX is in a downtrend. The stock is trading at $88.18, which leaves it 9.32% below its 50-day average of $97.24 and 9.18% below its 200-day average of $97.10. Near the bottom of its 52-week range, the price is 10.89% above the low of $79.52 and 28.89% below the high of $124.00.
The price is down over each of these periods: 10.30% over the past month, 2.65% over the past three months and 15.75% over the past year. The 14-day RSI of 40.7 is in the neutral zone, and the MACD line is negative.
Rating reaffirmed ›
Canaccord Genuity kept its Buy rating on October 14, 2026.
Source: Analyst action, Canaccord Genuity, October 14, 2026
Earnings miss ›
The May 5, 2026 report missed the EPS estimate by 1.56%, and the share price fell 0.25% in the first session after it.
Source: Earnings report, May 5, 2026Analyst downgrade ›
BMO Capital downgraded it to Market Perform from Outperform on September 8, 2026.
Source: Analyst action, BMO Capital, September 8, 2026
- Two levels matter most right now: the 20-day EMA at $90.79 sits above the price, and the 52-week low at $79.52 sits below it.
- A 14-day RSI of 40.7 is neutral, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum in either direction.
- The share price fell 0.25% in the first session after the May 5, 2026 report. Across the 6 reports in our data, BNTX beat estimates in 2 of them.
BNTX is in a downtrend, trading below both its 50-day average of $97.24 and its 200-day average of $97.10. A recovery would first need to reclaim the 200-day average, which would be the first sign of repair. The closest level above the price is the 20-day EMA at $90.79.
The next level below the price is the 52-week low at $79.52.
Technical indicators
Momentum and trend for BNTX, from its daily closes.
As of October 30, 2026, with BNTX at $88.18, its 14-day RSI is 40.7 (neutral territory), its 50-day simple moving average is $97.24 and its 200-day is $97.10.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What BNTX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, BNTX's 1-year correlation of daily returns is +0.29 with S&P 500 (SPY), +0.24 with Nasdaq 100 (QQQ), +0.24 with Bitcoin (BTC) and +0.18 with gold (XAU).
BNTX price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
14 of 21 analysts rate it a buy or strong buy, 7 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $121.99 is 38.3% above the price.No more buy ratings than three months ago ›
14 of 21 rate it a buy now, against 15 of 20 three months ago.
BNTX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 14, 2026 | Canaccord Genuity | Maintains | Buy |
| Oct 7, 2026 | Morgan Stanley | Maintains | Overweight |
| Sep 8, 2026 | BMO Capital | Downgrade | Market Perform |
| Aug 31, 2026 | Canaccord Genuity | Maintains | Buy |
| Aug 5, 2026 | Citigroup | Maintains | Buy |
| Aug 5, 2026 | Evercore ISI Group | Maintains | Outperform |
As of October 30, 2026, 21 Wall Street analysts cover BNTX: 14 rate it a buy or strong buy, 7 a hold and 0 a sell or strong sell. Their 12-month price targets range from $75.90 to $143.81. The median BNTX price target is $121.99, 38.3% above the price of $88.18.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
BNTX trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
BNTX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Short entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from BNTX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much BNTX tends to move, against the market and on its own.
BNTX price history and drawdowns
BNTX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move of 2% or more ›
The price has moved 2.21% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 81.9%, from August 2021 to July 2024; the price is still 80.0% below that peak.Most 1-year holds did not end higher ›
43% of 1-year holding periods in the last 7 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2019 is now worth $63,409, against $28,986 in the S&P 500 (SPY).
BNTX Drawdowns & Recovery
As of October 30, 2026, BNTX's worst peak-to-trough fall over the last 7 years with dividends reinvested was -81.9% (August 2021 to July 2024); it is still 80.0% below that peak, and 43% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into BNTX in October 2019 is worth now, against the same amount in the S&P 500.
Against the market: BNTX beat the S&P 500 over this period: $63,409 against $28,986.
A $10,000 investment in BNTX in October 2019 would be worth about $63,409 today with dividends reinvested, compared with about $28,986 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to BNTX, and which have not.
Strongest month, November: an average of +13.93%, up in 6 of 7 years.
Weakest month, January: an average of -3.46%, up in 3 of 7 years.
This month, October: has averaged +2.98%, up in 4 of 6 years. Past seasonality does not repeat on schedule.
Over the last 7 years, BNTX's strongest calendar month has been November (average +13.93%, up in 6 of 7 years) and its weakest January (average -3.46%, up in 3 of 7 years).
Average return for each calendar month over the last 7 years, from weekly closing prices with dividends included.
BNTX stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in BNTX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 7 years of price history, projects that a $10,000 investment in BNTX today could grow to about $15,348 by 2030 in the base case, with a 90th-percentile outcome near $55,289 and a 10th-percentile outcome around $4,260. Projections are statistical simulations, not guarantees.
BNTX Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $135 for BNTX by 2030 in the base case, from $88.18 today (1.5x over 4 years). The 10th-percentile path ends near $37.57. These are outcomes of a Monte Carlo simulation run on BNTX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $51.71 | $98.15 | $186 | |
| 2028 | $44.14 | $109 | $270 | |
| 2029 | $40.08 | $122 | $369 | |
| 2030 | $37.57 | $135 | $488 |
Method: a lognormal simulation of BNTX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. BNTX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. How the simulation works
BNTX insider trading
What the people running the company have bought and sold.
BNTX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought BNTX shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 30, 2026, BNTX insiders reported 12 open-market sales worth $74.3M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 24.0K | $2.3M |
| Oct 6, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 93.0K | $9.0M |
| Sep 30, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 66.0K | $6.5M |
| Sep 28, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 61.0K | $6.0M |
| Sep 24, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 69.0K | $6.8M |
| Sep 22, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 79.0K | $7.9M |
| Sep 16, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 49.0K | $4.7M |
| Sep 14, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 86.0K | $8.4M |
| Sep 10, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 20.5K | $2.0M |
| Sep 9, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 73.0K | $7.2M |
| Sep 4, 2026 | Ugur Sahin, MD
Chief Executive Officer
|
Sell | 76.5K | $7.9M |
| Apr 22, 2026 | Sierk Poetting
Chief Operating Officer
|
Sell | 50.0K | $5.5M |
Source: TwelveData, from reported insider filings
BNTX stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.